Skip to main content

COVID-19 Update

CSL continues to provide medicines to patients around the world.


Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world.We’realsoexploring new ways to specifically help those affected by COVID-19.In addition, we have taken measures to support the health and well-being of our people. We continue to closely monitor the outbreak to minimize business impact. (CSL is the parent company of CSL Behring and Seqirus)


Our Efforts:


We have joined with other leading plasma companies to form the CoVIg-19 Plasma Alliance, an unprecedented industry collaboration with a goal of developing and delivering CoVIg-19, a potential plasma-derived therapy for treating thosewith serious complications from COVID-19. We’re also partnering with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, to advance and deliver a novel immunotherapy targeting COVID-19.To see what else we’re doing to address the global pandemic, please see our Fact Sheet


Our People:


We have taken numerous steps to help ensure the health and safety of our workforce. This includes restricting international travel until July 1, 2021, postponing large group meetings, and encouraging employees to leverage various communication technologies to minimize business disruption.


Our Patients & Products:


CSL continues to provide an uninterrupted supply of our medicines around the world. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.

We have ongoing clinical trials at investigational sites worldwide and remain in close contact with researchers who are involved in this important work to evaluate promising new medicines, discussing the best ways to manage patient visits and follow-up appointments.We are supporting the University of Queensland (AUS) in its effort to develop a COVID-19 vaccine by providing technical expertise. As part of this partnership, we have made a donation of our company’s proprietary adjuvant technology, MF59®, to the university’s pre-clinical development program.


Our Donors:


Our plasma collection network is operational. Our plasma centers are committed to the highest standards of quality and safety for our employees and donors.